Walter Schippinger

Summary

Affiliation: Medical University of Graz
Country: Austria

Publications

  1. ncbi The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer
    Walter Schippinger
    Medizinische Universitätsklinik Graz, Klinische Abteilung für Onkologie, A 8036 Graz, Austria
    Oncol Rep 11:1331-6. 2004
  2. pmc A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    W Schippinger
    Department of Internal Medicine, Medical University of Graz, A 8036 Graz, Austria
    Br J Cancer 97:1021-7. 2007
  3. pmc A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    W Schippinger
    Medical Department, Division of Oncology, Graz Medical School, A 8036 Graz, Austria
    Br J Cancer 92:1655-62. 2005
  4. ncbi Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer
    Walter Schippinger
    Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    Virchows Arch 449:24-30. 2006
  5. ncbi Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim
    Walter Schippinger
    Division of Medical Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria
    Oncology 70:290-3. 2006
  6. ncbi The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer
    Walter Schippinger
    Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria
    Am J Clin Pathol 128:630-7. 2007
  7. pmc Plasmapheresis reverses all side-effects of a cisplatin overdose--a case report and treatment recommendation
    Guenter Hofmann
    Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    BMC Cancer 6:1. 2006
  8. ncbi Change of HER-2/neu status in a subset of distant metastases from breast carcinomas
    Peter Regitnig
    Department of Pathology, Medical University of Graz, Austria
    J Pathol 203:918-26. 2004
  9. ncbi IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer
    Ellen Heitzer
    Institute of Human Genetics, Medical University of Graz, Graz, Austria
    Pain Physician 15:499-510. 2012
  10. ncbi The functional polymorphism of erythropoietin gene rs1617640 G>T is not associated with susceptibility and clinical outcome of early-stage breast cancer
    Joanna Szkandera
    Division of Clinical Oncology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    Anticancer Res 32:3473-8. 2012

Collaborators

Detail Information

Publications15

  1. ncbi The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer
    Walter Schippinger
    Medizinische Universitätsklinik Graz, Klinische Abteilung für Onkologie, A 8036 Graz, Austria
    Oncol Rep 11:1331-6. 2004
    ..Decrease of elevated serum HER-2/neu to levels </=15 ng/ml and levels continuously </=15 ng/ml during the course of disease correlated significantly with longer survival...
  2. pmc A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
    W Schippinger
    Department of Internal Medicine, Medical University of Graz, A 8036 Graz, Austria
    Br J Cancer 97:1021-7. 2007
    ..However, in this study with limited power to detect small differences between the study arms, adjuvant chemotherapy failed to significantly improve DFS and OS...
  3. pmc A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    W Schippinger
    Medical Department, Division of Oncology, Graz Medical School, A 8036 Graz, Austria
    Br J Cancer 92:1655-62. 2005
    ..Interferon alfa had no significant influence on survival when combined with adjuvant 5-FU, but increased the toxicity of therapy substantially...
  4. ncbi Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer
    Walter Schippinger
    Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    Virchows Arch 449:24-30. 2006
    ..In conclusion, SAR is significantly longer in patients with AR-expressing breast carcinoma. However, AR expression is not an independent prognostic factor for SAR in metastatic breast cancer...
  5. ncbi Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim
    Walter Schippinger
    Division of Medical Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria
    Oncology 70:290-3. 2006
    ....
  6. ncbi The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer
    Walter Schippinger
    Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria
    Am J Clin Pathol 128:630-7. 2007
    ..Results demonstrate prechemotherapy serum HER-2/neu to be a significant predictor of response to neoadjuvant anthracycline-based chemotherapy for breast cancer...
  7. pmc Plasmapheresis reverses all side-effects of a cisplatin overdose--a case report and treatment recommendation
    Guenter Hofmann
    Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    BMC Cancer 6:1. 2006
    ..Nevertheless, it has several potential side effects affecting different organ systems and an overdose may lead to life-threatening complications and even death...
  8. ncbi Change of HER-2/neu status in a subset of distant metastases from breast carcinomas
    Peter Regitnig
    Department of Pathology, Medical University of Graz, Austria
    J Pathol 203:918-26. 2004
    ..On the basis of these results, there is evidence that in a subset of breast carcinomas, HER-2/neu amplification and overexpression occur de novo in distant metastases at a late disease stage...
  9. ncbi IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer
    Ellen Heitzer
    Institute of Human Genetics, Medical University of Graz, Graz, Austria
    Pain Physician 15:499-510. 2012
    ..To date, there exists no published correlation between biological, measurable biomarkers and pain intensity...
  10. ncbi The functional polymorphism of erythropoietin gene rs1617640 G>T is not associated with susceptibility and clinical outcome of early-stage breast cancer
    Joanna Szkandera
    Division of Clinical Oncology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria
    Anticancer Res 32:3473-8. 2012
    ..24, 95% confidence interval=1.82-1.90, p=0.31). In conclusion, our findings suggest a lack of influence of EPO rs1617640 G>T on early-stage breast carcinogenesis and clinical outcome...
  11. doi [Palliative sedation therapy for severe dyspnoea]
    Walter Schippinger
    Abteilung fur Innere Medizin, Albert Schweitzer Klinik, Graz, Austria
    Wien Med Wochenschr 160:338-42. 2010
    ..On the basis of this case study, indications, drugs, therapy monitoring and ethical aspects of palliative sedation therapy are discussed...
  12. ncbi Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial
    Peter Schmid
    Department of Oncology and Hematology, Charite Campus Mitte, Humboldt University Berlin, Schumannstrasse 20 21, 10117 Berlin, Germany
    J Clin Oncol 23:432-40. 2005
    ..Trials with late intensification HDCT have failed to show an advantage in overall survival. This study was initiated to compare up-front tandem HDCT and standard combination therapy in patients with metastatic breast cancer...
  13. doi Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy
    Margaretha Rudas
    Department of Pathology, Medical University of Vienna, Austria
    Clin Cancer Res 14:1767-74. 2008
    ..The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy...
  14. doi Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy
    Peter Dubsky
    Department of Surgery, Medical University Vienna, Vienna, Austria
    Clin Cancer Res 14:2082-7. 2008
    ....
  15. ncbi Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer
    Jörg Schneider
    Division of Molecular Genome Analysis, German Cancer Research Center, Heidelberg 69120, Germany
    Int J Cancer 119:2974-9. 2006
    ..In summary, the expression of few genes is sufficient to determine ER status. Future decisions on antiestrogen based therapy in breast cancer could be based on this signature rather than on immunostaining alone...